TICKERNERD
Menu
HELPHealthcare · Biotechnology

HELP Stock Forecast: Helus Pharma, Inc. Price Predictions for 2026-2027

Last close, 12 Oct 2026
$11
−6.53% on the day

The 11 Wall Street analysts covering Helus Pharma, Inc. hold a median 12-month price target of $43 — +288.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 9 Oct 2026 — in the lower half.

Market cap
$806.0M
Ticker Nerd rank
48 / 100
Median analyst target
$43
Analysts covering
11
Revenue$0.0
Operating income−$49.1M
Net income−$47.8M
Free cash flow−$37.4M
Quarterly, 7 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.4%
1M
−15.0%
YTD
+34.8%
1Y
+83.2%
From 52W high
−21.3%
From 52W low
+185.0%
$4
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HELP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Helus Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 9 Oct 2026
48 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
99
Momentum
81
Accruals
61
Issuance
58
Revisions
44
Quality
41
Volatility
40
Growth
24
Value
11

Size (99): Smaller than most of the companies we track.

Value (11): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

HELP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HELP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Jan 26Apr 26Jul 26Oct 26HELPHigh $70Median $43Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
11 Buy0 Hold0 Sell
Low $15Median $43High $70

The green dot is the last close — the median target sits +288.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 Sept 2026BarclaysInitiatesOverweight$35
18 Sept 2026BarclaysInitiatesOverweight$35
20 Aug 2026TD CowenMaintainsBuy$8.00 → $62
20 Aug 2026TD CowenMaintainsBuy—
27 July 2026Wells FargoInitiatesOverweight—
27 July 2026Wells FargoInitiatesOverweight$16
9 July 2026HC Wainwright & Co.MaintainsBuy$95 → $70
9 July 2026HC Wainwright & Co.MaintainsBuy—
1 July 2026Canaccord GenuityMaintainsBuy—
13 Apr 2026TD CowenInitiatesBuy—
2 Mar 2026HC Wainwright & Co.MaintainsBuy—
3 Dec 2025GuggenheimMaintainsBuy—
20 Nov 2025Canaccord GenuityMaintainsBuy—
14 Nov 2025HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HELP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

HELP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 12 Oct 2026, Helus Pharma, Inc. returned +83.2% against +20.4% for the S&P 500, dividends included.

HELP vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250Jan 26Apr 26Jul 26Oct 26HELPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

HELP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Helus Pharma, Inc. (HELP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.6×

Cheaper than 87% of US stocks

Price / sales
—
Price / book
2.8×

Cheaper than 33% of US stocks

EV / EBITDA
−3.8×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−86.9%

Higher than 15% of US stocks

Return on assets
−44.4%

Higher than 9% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Helus Pharma, Inc. (HELP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Helus Pharma, Inc. has a market value of $806.0M and an enterprise value of $639.5M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$171.2M.

  • Free cash flow in the twelve months to 30 June 2026: −$142.3M.

  • Shares outstanding: 62.0M.

  • Trailing P/E: −2.6×; forward P/E: −6.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Helus Pharma, Inc. employs 100 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Oct 2026

Data provided by Twelve Data

Peers

HELP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
HELPHelus Pharma, Inc.$806.0M
48
CRISCuris, Inc.$1.3M
37
MLECMoolec Science SA$1.3M
4
ARTLArtelo Biosciences, Inc.$1.7M
17
LABTLakewood-Amedex Biotherapeutics, Inc.$1.7M
21
BBLGBone Biologics Corp.$1.3M
22
OGENOragenics, Inc.$1.9M
10

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Helus Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HELP news & analysis

Helus Pharma: A Buy Ahead Of The HLP003 Phase 3 Readout

Seeking Alpha · 11 Oct 2026positive

Helus Pharma is reported as a buy ahead of HLP003’s Phase 3 APPROACH topline data, expected in 4Q26. The item cites prior Phase 2 results and the company’s cash balance, while noting high operating outflows and dilution risk from its $100 million ATM facility.

Why it matters — The Phase 3 readout is identified as a key near-term catalyst, while cash runway and potential dilution are factors HELP watchers may track.

Helus Pharma Announces Completion of Legal Name Change

GlobeNewsWire · 1 Oct 2026neutral

Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, announced its legal name has been changed from "Cybin Inc." to "Helus Pharma Inc." effective October 1, 2026. The name change was approved by shareholders at the company's annual and special meeting held on September 22, 2026.

Why it matters — HELP watchers should be aware that the company's official legal name has changed to Helus Pharma Inc., which affects how the company is formally identified going forward.

Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression

MarketBeat · 24 Sept 2026neutral

Helus Pharma, formerly Cybin (NASDAQ: HELP), outlined its late-stage development plans for HLP-003 in adjunctive major depressive disorder and discussed its broader pipeline of serotonergic agonists during TD Cowen's Novel Mechanisms in Neuropsychiatry virtual summit.

Why it matters — A HELP watcher would care because the company detailed the path toward Phase III data for its lead MDD candidate, HLP-003, giving a clearer timetable for a key value-driving milestone.

Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change

GlobeNewsWire · 22 Sept 2026neutral

Helus Pharma announced the voting results from its annual and special meeting of shareholders held on September 22, 2026, attended by 107 shareholders representing 63.58% of outstanding shares. The company also announced the effective date for its legal name change.

Why it matters — Shareholders of Helus Pharma would want to track the outcome of the meeting's votes and the company's upcoming legal name change, which could affect how the entity is identified in the market.

FAQ

Frequently asked questions about HELP stock

What is the HELP stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Helus Pharma, Inc. have a median 12-month price target of $43, with estimates ranging from $15 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HELP stock a buy right now?

Of the 11 analysts covering Helus Pharma, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Helus Pharma, Inc. 48 out of 100 across roughly 4,600 US stocks as at 9 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HELP?

As at 9 Oct 2026, Helus Pharma, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).

Will HELP stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +288.5% from the last close, and Ticker Nerd's factor model ranks Helus Pharma, Inc. 48 out of 100 as at 9 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HELP stock forecast for 2030?

No analyst covering Helus Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HELP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $70 over the next 12 months.

How has HELP stock performed over the past year?

Helus Pharma, Inc. returned +83.2% over the 12 months to 12 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Helus Pharma, Inc. do?

Helus Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for mental health conditions, with a particular emphasis on serotonergic compounds and psychedelic-based medicines.

What is the latest news on HELP?

The most recent item we track (Seeking Alpha, 11 Oct 2026): "Helus Pharma: A Buy Ahead Of The HLP003 Phase 3 Readout". Helus Pharma is reported as a buy ahead of HLP003’s Phase 3 APPROACH topline data, expected in 4Q26. The item cites prior Phase 2 results and the company’s cash balance, while noting high operating outflows and dilution risk from its $100 million ATM facility.

Company

About Helus Pharma, Inc.

Helus Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for mental health conditions, with a particular emphasis on serotonergic compounds and psychedelic-based medicines. The company’s current pipeline centers on proprietary novel serotonergic agonists designed to act on serotonin pathways and support neuroplasticity, including candidates under development for depression and anxiety disorders. Helus Pharma Inc. works across preclinical and clinical research, advancing programs through studies aimed at psychiatric and neurological applications. The company serves the biotechnology and pharmaceutical sectors, where it contributes to the broader effort to expand treatment options for patients with unmet mental health needs. Headquartered in Toronto, Canada, Helus Pharma Inc. is positioned as a research-driven developer of innovative neuropsychiatric therapeutics.

CEO Mr. Michael I. Halstead J.D. · 100 employees · Canada · https://www.helus.com